Figure 1.
Flow diagram of study selection.
Table 1.
Characteristics of included studies.
Figure 2.
The aggregate estimate for the frequency of MGMT promoter methylation in elderly glioblastoma patients.
Figure 3.
outcome: OS; comparison: methylated versus unmethylated: A. TMZ-free therapies; B. TMZ-containing therapies. (tmz = temozolomide; rt = radiotherapy; sc = supportive care; crt = chemoradiotherapy).
Figure 4.
outcome: OS; comparison: TMZ-containing therapies versus TMZ-free therapies: A. methylated tumors; B. unmethylated tumors.
Table 2.
Additional results of the subgroup and interaction analyses.